Andira is a private pharmaceutical technology company commercializing breakthrough advancements for infection control.
Andira uses a validated R&D platform to transform existing pharmaceutical agents into advanced next-generation solutions with improved efficacy by harnessing pharmacologic synergy.
Andira is targeting near-term market approval of Matrix3™ Shield for infection control in advanced wound care.
Andira has multiple healthcare innovations in its pipeline and holds a global portfolio of patented and patent-pending breakthroughs for infection control, cancer therapy, pain management and enhanced drug delivery.
Andira endeavors to raise the medical standard of care with its breakthrough patented and patent-pending technologies by delivering next-generation healthcare products.
Andira is uniquely positioned as the only company having two validated triple synergy anti-bacterial technologies that contain standard-of-care infection control agents that are approved and already in use worldwide.
Andira’s lead product for infection control is Matrix3™ Shield, an anti-infective medical device for advanced wound care. The breakthrough technology backing the product is Matrix3™, a triple synergy silver-based agent for the prevention and treatment of infections, including those caused by antibiotic resistant “superbug” bacteria.
Matrix3™ has shown over 1,000,000 times better performance and faster onset of action than silver alone – a mainstay infection control agent incorporated into healthcare products globally. Silver-based Matrix3™ anti-infective technology is suitable for use in medical devices, wound care, surface coatings and topically-applied drug products. For example, wound dressings formulated with silver for infection control are a $1 billion USD global market. Learn more about Matrix3™ and Andira’s portfolio of pharmaceutical technologies below.
